Scarica l'app Stockscreener
53.39
1.64%
-0.89
Dopo l'orario di chiusura:
53.33
-0.06
-0.11%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Gsk Plc Adr Borsa (GSK) Ultime notizie
FDA Broadens Access To GSK's Respiratory Syncytial Virus Shot For Younger High-Risk Adults - Benzinga
GSK Out-Licenses Rights for Rare Liver Disease Drug to Alfasigma - Finviz
GSK PLC Sponsored ADR (NYSE:GSK) Receives Average Recommendation of "Reduce" from Analysts - MarketBeat
GSK PLC Sponsored ADR $GSK Shares Sold by Quantbot Technologies LP - MarketBeat
Price Over Earnings Overview: GSK - Sahm
GlaxoSmithKline Pharma: Can India’s GSK Arm Still Reward US Investors? - AD HOC NEWS
GSK PLC Sponsored ADR $GSK Shares Sold by Kahn Brothers Group Inc. - MarketBeat
GSK PLC Sponsored ADR (NYSE:GSK) Short Interest Down 26.3% in February - MarketBeat
CapEx per share of GSK PLC ADR Cert.Deposito Arg.Repr. 0.25 ADRs – BCBA:GSKD - TradingView
Fisher Asset Management LLC Purchases 889,210 Shares of GSK PLC Sponsored ADR $GSK - MarketBeat
Antibiotics Market - GlobeNewswire Inc.
GSK Stock Price, Quote & Chart | GSK PLC-SPON ADR (NYSE:GSK) - ChartMill
GSK Expands Pipeline With $950 Million Pulmonary Hypertension Power Play - Sahm
SMMT Incurs Wider-Than-Expected Q4 Loss, Pipeline Progress in Focus - Finviz
GSK (GSK) Announces 75.6% Vaccine Effectiveness for Arexvy in Real-World RSV Study - Finviz
Moderna Stock Jumps After FDA Reverses Course on Flu Shot - TradingView
GlaxoSmithKline Pharma: Quiet India Move, Big Signal for U.S. Portfolios? - AD HOC NEWS
GSK plc (GSK) Q4 Results Topped Forecasts as Specialty Medicines Jump 17% - Finviz
GSK PLC Sponsored ADR (NYSE:GSK) Receives Consensus Rating of "Reduce" from Brokerages - MarketBeat
GSK PLC Sponsored ADR (NYSE:GSK) Receives Consensus Rating of “Reduce” from Brokerages - Defense World
Is GSK PLC Gaining or Losing Market Support? - Sahm
BI Asset Management Fondsmaeglerselskab A S Reduces Stake in GSK PLC Sponsored ADR $GSK - MarketBeat
GSK Gets EU Approval for Expanded Use of Nucala in COPD - Finviz
GSK PLC Sponsored ADR (NYSE:GSK) Declares Dividend Increase$0.49 Per Share - MarketBeat
ANALYSIS-Novo Nordisk risks weight-loss price war as discount pressures deepen - Sahm
3 International Stocks to Buy for 2026 - Morningstar
GSK Set up for Steady Long-Term Growth as Portfolio and Pipeline Develop - Morningstar
GSK's Q4 Earnings & Sales Beat Estimates, Stock Up on '26 Outlook - TradingView
10 best global blue-chip stocks to buy for the long term - Morningstar Australia
GSK plc (ADR): Quiet Rally, Loud Expectations – Is the Stock Finally Escaping Its Legal Overhang? - AD HOC NEWS
GSK (GSK) Reports Next Week: Wall Street Expects Earnings Growth - Finviz
10 Best Blue-Chip Stocks to Buy for the Long Term - Morningstar
Corticosteroids Market Report 2026 - GlobeNewswire Inc.
Oncolytic Virotherapy Market - GlobeNewswire Inc.
GSK to Boost Respiratory & Immunology Pipeline With $2.2B RAPT Buyout - Finviz
GSK plc (ADR): Defensive pharma heavyweight tests investors’ patience as Wall Street edges cautiou - AD HOC NEWS
GSK To Acquire RAPT Therapeutics In $2.2 Billion Bet On Food Allergy Breakthrough - Sahm
Jakub Rochlitz @TheDividendFund: "𝗜𝘀 𝘁𝗵𝗲 "𝗔𝗜-𝗮𝘁-𝗮𝗻𝘆-𝗰𝗼𝘀𝘁" 𝗲𝗿𝗮 𝗰𝗼𝗼𝗹𝗶𝗻𝗴..." - eToro
1.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):